7CU5
| N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Programmed cell death protein 1, ... | Authors: | Liu, K.F, Tan, S.G, Jin, W.J, Guan, J.W, Wang, W.L, Sun, H, Qi, J.X, Yan, J.H, Chai, Y, Wang, Z.F, Chu, X.D, Gao, G.F. | Deposit date: | 2020-08-21 | Release date: | 2020-10-14 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.81 Å) | Cite: | N-glycosylation of PD-1 promotes binding of camrelizumab. Embo Rep., 21, 2020
|
|
7CGW
| Complex structure of PD-1 and tislelizumab Fab | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of tislelizumab Fab, Light chain of tislelizumab Fab, ... | Authors: | Hong, Y, Feng, Y.C, Liu, Y. | Deposit date: | 2020-07-02 | Release date: | 2021-04-07 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (3.2 Å) | Cite: | Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. Febs Open Bio, 11, 2021
|
|
7C88
| Complex structure of JS003 and PD-L1 | Descriptor: | JS003 Heavy chain, JS003 Light chain, Programmed cell death 1 ligand 1 | Authors: | Bi, X, Shi, R, Chai, Y, Qi, J, Yan, J, Tan, S. | Deposit date: | 2020-05-29 | Release date: | 2021-04-14 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.997 Å) | Cite: | Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Signal Transduct Target Ther, 5, 2020
|
|
7CZD
| Crystal structure of PD-L1 in complex with a VHH | Descriptor: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, Programmed cell death 1 ligand 1, ... | Authors: | Wang, C. | Deposit date: | 2020-09-08 | Release date: | 2021-07-14 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.64 Å) | Cite: | Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. J Immunother Cancer, 9, 2021
|
|
7ELX
| The crystal structure of CTLA-4 and Fab | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain of Fab, light chain of Fab | Authors: | Yu, X.J, Wang, L, Yu, C.F. | Deposit date: | 2021-04-12 | Release date: | 2021-06-30 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.14 Å) | Cite: | The crystal structure of CTLA-4 and Fab To Be Published
|
|
7E9B
| |
7DV4
| Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4 | Descriptor: | 1,2-ETHANEDIOL, 4003-1(VH), Cytotoxic T-lymphocyte protein 4 | Authors: | Li, H, Gan, X, He, Y. | Deposit date: | 2021-01-12 | Release date: | 2022-01-12 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.38 Å) | Cite: | An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile. Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
7DY7
| Discovery of Novel Small-molecule Inhibitors of PD-1/PD-L1 Axis that Promotes PD-L1 Internalization and Degradation | Descriptor: | 2-[[3-[[5-(2-methyl-3-phenyl-phenyl)-1,3,4-oxadiazol-2-yl]amino]phenyl]methylamino]ethanol, Programmed cell death 1 ligand 1 | Authors: | Cheng, Y, Wang, T.Y, Lu, M.L, Jiang, S, Xiao, Y.B. | Deposit date: | 2021-01-20 | Release date: | 2022-01-26 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.42 Å) | Cite: | Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. J.Med.Chem., 65, 2022
|
|
6RQM
| |
6RP8
| |
6RPG
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | Descriptor: | Programmed cell death 1 ligand 1, ~{N}-[2-[[4-[[3-[3-[[4-[(2-acetamidoethylamino)methyl]-5-[(5-cyanopyridin-3-yl)methoxy]-2-methyl-phenoxy]methyl]-2-methyl-phenyl]-2-methyl-phenyl]methoxy]-2-[(5-cyanopyridin-3-yl)methoxy]-5-methyl-phenyl]methylamino]ethyl]ethanamide | Authors: | Magiera-Mularz, K, Basu, S, Yang, J, Xu, B, Skalniak, L, Musielak, B, Kholodovych, V, Holak, T.A, Hu, L. | Deposit date: | 2019-05-14 | Release date: | 2019-07-24 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Design, Synthesis, Evaluation, and Structural Studies ofC2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. J.Med.Chem., 62, 2019
|
|
6SM1
| Wild type immunoglobulin light chain (WT-1) | Descriptor: | CALCIUM ION, DI(HYDROXYETHYL)ETHER, Immunoglobulin lambda variable 2-14, ... | Authors: | Kazman, P, Vielberg, M.-T, Cendales, M.D.P, Hunziger, L, Weber, B, Hegenbart, U, Zacharias, M, Koehler, R, Schoenland, S, Groll, M, Buchner, J. | Deposit date: | 2019-08-21 | Release date: | 2020-03-18 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.55 Å) | Cite: | Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation. Elife, 9, 2020
|
|
6SRU
| Structure of Ig-like V-type domian of mouse Programmed cell death 1 ligand 1 (PD-L1) | Descriptor: | Programmed cell death 1 ligand 1 | Authors: | Magiera-Mularz, K, Sala, D, Grudnik, P, Holak, T.A. | Deposit date: | 2019-09-06 | Release date: | 2021-02-03 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (2.532 Å) | Cite: | Human and mouse PD-L1: similar molecular structure, but different druggability profiles. Iscience, 24, 2021
|
|
6U6V
| Crystal structure of human PD-1H / VISTA | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, V-type immunoglobulin domain-containing suppressor of T-cell activation | Authors: | Slater, B.T, Han, X, Chen, L, Xiong, Y. | Deposit date: | 2019-08-30 | Release date: | 2020-01-01 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural insight into T cell coinhibition by PD-1H (VISTA). Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6TXZ
| FAB PART OF M6903 IN COMPLEX WITH HUMAN TIM3 | Descriptor: | Fab H, Fab L, Hepatitis A virus cellular receptor 2 | Authors: | Musil, D, Sood, V. | Deposit date: | 2020-01-15 | Release date: | 2020-04-08 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (3.06 Å) | Cite: | Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody. Oncoimmunology, 9, 2020
|
|
6UMV
| Human apo PD-1 double mutant | Descriptor: | CHLORIDE ION, Programmed cell death protein 1 | Authors: | Tang, S, Kim, P.S. | Deposit date: | 2019-10-10 | Release date: | 2019-11-27 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.424 Å) | Cite: | A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6UMU
| Human apo PD-1 triple mutant | Descriptor: | CHLORIDE ION, Programmed cell death protein 1 | Authors: | Tang, S, Kim, P.S. | Deposit date: | 2019-10-10 | Release date: | 2019-11-27 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.183 Å) | Cite: | A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6UMT
| High-affinity human PD-1 PD-L2 complex | Descriptor: | MAGNESIUM ION, Programmed cell death 1 ligand 2, Programmed cell death protein 1 | Authors: | Tang, S, Kim, P.S. | Deposit date: | 2019-10-10 | Release date: | 2019-11-27 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.986 Å) | Cite: | A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6V3P
| |
1A6W
| |
1A7N
| |
1A8J
| |
1A7P
| |
1AC6
| |
1A7Q
| FV FRAGMENT OF MOUSE MONOCLONAL ANTIBODY D1.3 (BALB/C, IGG1, K) HIGH AFFINITY EXPRESSED VARIANT CONTAINING SER26L->GLY, ILE29L->THR, GLU81L->ASP, THR97L->SER, PRO240H->LEU, ASP258H->ALA, LYS281H->GLU, ASN283H->ASP AND LEU312H->VAL | Descriptor: | IGG1-KAPPA D1.3 FV (HEAVY CHAIN), IGG1-KAPPA D1.3 FV (LIGHT CHAIN) | Authors: | Marks, C, Henrick, K, Winter, G. | Deposit date: | 1998-03-16 | Release date: | 1998-04-29 | Last modified: | 2023-08-09 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | X-Ray Structures of D1.3 Fv Mutants To be Published
|
|